Vandetanib for the second and subsequent line treatment of non-small cell lung cancer after previous platinum containing chemotherapy
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 November 2008
Topic area
  • Cancer
  • Respiratory

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Alice Law
Executive Lead: Andrew Stevens
Project manager: Laura Malone
Technical Lead: Sally Gallaugher


Key events during the development of the guidance:

Date Update
25 November 2009 The manufacturer of vandetanib has advised us that regulatory approval for this technology in the second and subsequent line setting is not being sought at this time. The Institute has therefore decided to remove this appraisal from its current work programme. As this topic has been referred to the Institute, we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Hall (020 7045 2240 or email:

For further information on our processes and methods, please see our CHTE processes and methods manual